Study of ALXN2050 in Participants With Renal Impairment
Study Identifier:
ALXN2050-HV-108
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
- Other
Study Drug
- Drug: ALXN2050
Date
Jul 2021 - Feb 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 80 Years
Requirements Information
Sex
Female & Male
Age
18 - 80 Years
Study Details
Medical Condition
- Unmapped
- Other
Study Drug
- Drug: ALXN2050
Date
Jul 2021 - Feb 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 80 Years years
Requirements Information
Protocol Summary
This study will investigate the impact of impaired renal function on the plasma pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future indications in individuals with impaired renal function.
Trial Locations
Location
Status
Location
Clinical Trial Site
Hialeah, Florida, United States, 33014
Status
N/A
Location
Clinical Trial Site
Orlando, Florida, United States, 32809
Status
N/A